Post-line Treatment with Teniposide for C-Myc-driven Extensive-stage Small Cell Lung Cancer

Launched by SHANGHAI PULMONARY HOSPITAL, SHANGHAI, CHINA · Jan 3, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a treatment called teniposide for patients with extensive-stage small cell lung cancer (ES-SCLC) who have not responded to previous chemotherapy. The trial specifically focuses on patients whose cancer is driven by a gene called c-Myc. Researchers want to see if teniposide is effective for these patients and how the gene's activity affects the treatment's success.

To be eligible for the study, participants need to be between 18 and 75 years old, have extensive-stage small cell lung cancer, and have experienced cancer progression after at least one chemotherapy treatment. Participants should be able to carry out daily activities with little to no assistance and must expect to live for at least three more months. The trial is not yet recruiting participants, but those interested will undergo a thorough health check to ensure they meet the criteria. Throughout the trial, participants will receive close monitoring and support from the research team.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. extensive stage small cell lung cancer
• • 2. Progression after receiving at least one chemotherapy drug treatment in the past;
• • 3. ECOG score 0-1
• • 4. c-Myc-driven
• • 5. Expected survival period ≥3 months
• • 6. Age: 18-75 years old;
• • 7. The informed consent form complies with the ICH-GCP principles.
• Exclusion Criteria:
• • 1. No measurable lesions
• • 2. Other severe and persistent diseases or organ system dysfunction;
• • 3. Women planning pregnancy or men planning family planning;
• • 4. Women who are pregnant or breastfeeding;
• • 5. Those who cannot follow the research protocol provided by the investigator.